SCHEMBL7122674

SCHEMBL7122674

c1nc(Nc2ccc3[nH]ccc3c2)c2sc(-c3ccc(CN4CCOCC4)cc3)cc2n1

nearest known ligand 0.79

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
EGFR P00533 17/20 0.79
FLT1 P17948 16/20 0.79
KDR P35968 1/20 0.66
PRKCQ Q04759 2/20 0.60
PRKCD Q05655 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7121036 0.91 FLT1 (0.75) EGFRFLT1KDRPRKCQPRKCD
SCHEMBL7116962 0.90 FLT1 (0.74) EGFRFLT1KDRPRKCQPRKCD
SCHEMBL7123755 0.89 FLT1 (0.68) EGFRFLT1KDRPRKCQPRKCD
SCHEMBL7117871 0.89 FLT1 (0.70) EGFRFLT1KDRPRKCQPRKCD
SCHEMBL7119457 0.88 EGFR (1.00) EGFRFLT1KDRPRKCQPRKCD
SCHEMBL7128094 0.87 FLT1 (0.63) EGFRFLT1KDRPRKCQPRKCD
SCHEMBL7124468 0.86 FLT1 (0.76) EGFRFLT1KDRPRKCQPRKCD
SCHEMBL7118450 0.85 FLT1 (1.00) EGFRFLT1KDRPRKCQPRKCD
SCHEMBL7115414 0.84 FLT1 (0.69) EGFRFLT1KDRPRKCQPRKCD
SCHEMBL7125012 0.84 FLT1 (1.00) EGFRFLT1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101328186-A Thienopyrimidine and thienopyridine derivatives useful as anticancer agents PFIZER PROD INC (US) 2008-12-24 CN claimed
US-20030162795-A1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents PFIZER INC. 2003-08-28 US claimed
CN-1280580-A Thienopyrimidine and thienopyridine derivatives as anticancer agents PFIZER PROD INC (US) 2001-01-17 CN claimed
CN-101328186-A Thienopyrimidine and thienopyridine derivatives useful as anticancer agents PFIZER PROD INC (US) 2008-12-24 CN disclosed
US-20030162795-A1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents PFIZER INC. 2003-08-28 US disclosed
US-6492383-B1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents PFIZER INC. 2002-12-10 US disclosed
CN-1280580-A Thienopyrimidine and thienopyridine derivatives as anticancer agents PFIZER PROD INC (US) 2001-01-17 CN disclosed
EP-1028964-A1 THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS Pfizer Products Inc. (US) 2000-08-23 EP disclosed
WO-1999024440-A1 THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PRODUCTS INC. (US) 1999-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162795-A1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents TYMP, DPYD, HPRT1 EGFR 2961/4885FLT1 1043/4885KDR 2362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.